Literature DB >> 12943724

Androgen treatment of male hypogonadism in older males.

John E Morley1, H M Perry.   

Abstract

The treatment of primary and secondary hypogonadism with testosterone is well established. Recently, there has been increased awareness that low testosterone levels also occur in chronically ill persons and aging males. Because of sex hormone binding globulin changes, it is more appropriate to make the diagnosis using either free or bioavailable testosterone. A small number of controlled studies have suggested that testosterone replacement in older men improves libido, quality of erections, some aspects of cognition, muscle mass, muscles strength, and bone mineral density. It also decreases fat mass and leptin levels. A number of screening questionnaires for the andropause have been developed. Insufficient numbers of older men have been treated with testosterone to characterize the true incidence of side effects. There is a desperate need for well designed, large controlled trials to establish the value or otherwise of testosterone treatment in older males.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943724     DOI: 10.1016/s0960-0760(03)00203-6

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  9 in total

Review 1.  The endocrine pharmacology of testosterone therapy in men.

Authors:  Michael Oettel
Journal:  Naturwissenschaften       Date:  2004-01-28

Review 2.  The treatment of late-onset hypogonadism.

Authors:  Oktay Üçer; Bilal Gümüş
Journal:  Turk J Urol       Date:  2014-03-24

Review 3.  Frailty and hormones.

Authors:  John E Morley; Moon Jong Kim; Matthew T Haren
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 4.  Lower urinary tract disease: what are we trying to treat and in whom?

Authors:  Jeremy P W Heaton
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 5.  Protective actions of sex steroid hormones in Alzheimer's disease.

Authors:  Christian J Pike; Jenna C Carroll; Emily R Rosario; Anna M Barron
Journal:  Front Neuroendocrinol       Date:  2009-05-07       Impact factor: 8.606

6.  Androgen therapy: testing before prescribing and monitoring during therapy.

Authors:  Alan Katz; Anne Katz; Charles Burchill
Journal:  Can Fam Physician       Date:  2007-11       Impact factor: 3.275

7.  Sex differences in the association between serum levels of testosterone and frailty in an elderly population: the Toledo Study for Healthy Aging.

Authors:  Laure Carcaillon; Carmen Blanco; Cristina Alonso-Bouzón; Ana Alfaro-Acha; Francisco-José Garcia-García; Leocadio Rodriguez-Mañas
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

Review 8.  The many faces of testosterone.

Authors:  Jerald Bain
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

9.  Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels.

Authors:  Minami Tasaki; Norio Yasui-Furukori; Saaya Yokoyama; Masataka Shinozaki; Norio Sugawara; Kazutaka Shimoda
Journal:  Neuropsychopharmacol Rep       Date:  2021-06-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.